Premium
Primary retroperitoneal seminoma
Author(s) -
Buskirk Steven J.,
Evans Richard G.,
Farrow George M.,
Earle John D.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820501)49:9<1934::aid-cncr2820490930>3.0.co;2-t
Subject(s) - medicine , seminoma , histopathology , mediastinum , lymph , radiation therapy , radiology , retrospective cohort study , primary tumor , surgery , chemotherapy , metastasis , cancer , pathology
In a retrospective review (1950–1975) of the Mayo Clinic experience with seminomas (483 cases), twelve patients (2.5%) were found to have a retroperitoneal seminoma without evidence of testicular involvement. The mean age was 47 years (range, 31–67). Eleven patients were treated by radiation alone, with doses ranging from less than 2,000–5,800 rads. Seven patients are alive with a median follow‐up of six years. The median survival of the five that died is ten months. Good prognostic factors are typical histopathology and an encapsulated tumor. Poor prognostic factors are atypical histopathology, a nonencapsulated tumor, a symptomatic abdominal mass and a nonfunctioning kidney at the time of diagnosis. Although the review includes few patients, it seems reasonable to suggest irradiation of the tumor bed and paraaortic lymph nodes to a minimum dose of 2,000 rads. Prophylactic treatment of the mediastinum and supraclavicular lymph nodes should be considered if one or more of the poor prognostic factors are present.